Two meta-analyses of the Non Small Cell Lung Cancer Meta-analyses Collaborative Group (NSCLC MACG) on the effects of adjuvant chemotherapy on early stage NSCLC after complete or curative resection have demonstrated that adjuvant cisplatin-based regimens are a valid and recommendable option following curative surgery. We discuss these results in the light of current interdisciplinary guidelines and existing meta-analyses of randomized clinical trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375, 1267–1277 (2010).
Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552–3559 (2008).
Goeckenjan, G. et al. Prevention, diagnosis, therapy, and follow-up of lung cancer [German]. Pneumologie 64 (Suppl. 2) e1–e164 (2010).
Pisters, K. M. et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable non small-cell lung cancer guideline. J. Clin. Oncol. 25, 5506–5518 (2007).
Butts, C. A. et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J. Clin. Oncol. 28, 29–34 (2010).
Arriagada, R. et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J. Clin. Oncol. 28, 35–42 (2010).
Robinson, L. A., Ruckdeschel, J. C., Wagner, H., Stevens, C. W. and the American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA. ACCP Evidence-based clinical practice guidelines (2nd edition). Chest 132 (Suppl. 3), 243S–265S (2007).
Aupérin, A. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 2181–2190 (2010).
Albain, K. S. et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trail. Lancet 374, 379–386 (2009).
Pöttgen, C. et al. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 76, 809–815 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Stuschke, M., Pöttgen, C. Effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol 7, 613–614 (2010). https://doi.org/10.1038/nrclinonc.2010.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.165
This article is cited by
-
High Sam68 expression predicts poor prognosis in non-small cell lung cancer
Clinical and Translational Oncology (2014)
